Clinical Trials Sponsored by ISA+Pharmaceuticals

Total 22342 results

Teva Pharmaceuticals USA

Completed

Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Desmopressin Acetate 0.2 mg Tablets, Fasting

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Finasteride 5 mg Tablets, Non-fasting

Healthy

United States
Teva Pharmaceuticals USA

Completed

Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed

Healthy

Canada
Teva Pharmaceuticals USA

Completed

A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Sumatriptan Succinate 100 mg Tablets Under Fasting Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Ropinirole 0.25 mg Tablets Under Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Glimepiride 4 mg Tablets Under Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Cilostazol 100 mg Tablet Formulations Under Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Ribavirin 200 mg Tablets Under Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Ramipril 10 mg Capsule in Healthy Subjects Under Fed Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Ursodiol 500 mg Tablets Under Fed Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Ursodiol Tablets 500 mg Under Fasting Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Mycophenolate Mofetil Tablets Under Fasting Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Cefdinir for Oral Suspension 250 mg/5mL, Fasting

Healthy

United States
Teva Pharmaceuticals USA

Completed

Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Trandolapril 4 mg Tablet Under Fasting Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets Under Fasting Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditions

Healthy

Canada
Teva Pharmaceuticals USA

Completed

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Risperidone 1 mg Tablets Dosed in Healthy Subjects Under Fed Conditions

Healthy

Canada
Taro Pharmaceuticals USA

Completed

A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.

Tinea Versicolor

United States
Teva Pharmaceuticals USA

Terminated

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

Seasonal Allergic Rhinitis

United States
Teva Pharmaceuticals USA

Completed

Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions

Healthy

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

Plaque Psoriasis

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing Oxymetazoline 1% Cream to RHOFADE

Bioequivalence

United States
Taro Pharmaceuticals USA

Completed

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

Tinea Pedis

United States
Teva Pharmaceuticals USA

Completed

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis

Actinic Keratosis

United States
Teva Pharmaceuticals USA

Withdrawn

An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc at Steady State Following Once-daily Administration of CASSIPA® in Opioid Dependent Subjects.

Evaluation of QTc Interval
Taro Pharmaceuticals USA

Completed

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Teva Pharmaceuticals USA

Completed

Pravastatin Sodium 40 mg Tablets Food Challenge Study

Healthy

Canada
Taro Pharmaceuticals USA

Completed

A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.

Secondarily Infected Traumatic Skin Lesions
Taro Pharmaceuticals USA

Completed

Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

Scalp Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS

Psoriasis

United States
Taro Pharmaceuticals USA

Completed

A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%

Lice; Head Lice

United States
Taro Pharmaceuticals USA

Completed

Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis

Tinea Pedis
Taro Pharmaceuticals USA

Completed

A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris

Acne Vulgaris
Taro Pharmaceuticals USA

Completed

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Acne Vulgaris
Taro Pharmaceuticals USA

Completed

Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis

Tinea Pedis

United States, Belize
Taro Pharmaceuticals USA

Completed

A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis

Tinea Pedis
Taro Pharmaceuticals USA

Completed

Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice

Pediculosis

India

3

Subscribe